(Reuters)—Regeneron Pharmaceuticals Inc. said on Tuesday it had identified hundreds of antibodies that could treat or prevent the coronavirus (COVID-19) and was preparing to begin clinical trials by early summer, sending the drugmaker’s shares up 12%. The company will select the top two antibodies to develop a “cocktail” treatment and scale up its manufacturing to…
HHS Relaxes HIPAA Enforcement
Effective immediately, the HHS Office for Civil Rights (OCR) has stated it will not impose any noncompliance penalties under the Health Insurance Portability and Accountability Act (HIPAA) on physicians using any non-public facing service or audio or video communication technology (e.g., Apple FaceTime, Skype, Facebook Messenger, etc.) for telehealth services. This discretion applies to telehealth…
CMS Relaxes Telehealth Restrictions
President Trump announced that CMS will broaden access to telehealth services during the COVID-19 pandemic. The CMS published a fact sheet outlining the types of visits that will be covered, the providers eligible to use the expanded services and coding considerations. The ACR is working with other specialty societies and the AMA to provide additional…
The Doctor Will See You Now: Legal & Regulatory Reforms Expand Telemedicine
In this time of COVID-19, you may be considering ways to deliver routine rheumatologic care via some form of telemedicine. Here are some of the legal considerations.
Statins Linked to Reduced Likelihood of Joint Replacement
NEW YORK (Reuters Health)—High-intensity statins are associated with a lower risk of joint replacement, new findings show. “Statins at high intensity may reduce the risk of hip and knee replacement. The effect may be RA specific,” Dr. Aliya Sarmanova of the University of Nottingham, U.K., and colleagues write in Rheumatology.1 Statins have anti-inflammatory effects, and…
Strong Support for Treat-to-Target Strategy in RA Patients
NEW YORK (Reuters Health)—In daily clinical practice, following a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) leads to higher rates of remission compared with not following a T2T strategy, according to a longitudinal analysis of real world data. “The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T,…
Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment
(Reuters)—Sanofi SA and partner Regeneron Pharmaceuticals Inc. have started a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a treatment for the coronavirus, the companies said on Monday. Enrolments for the mid-to-late stage trial will begin immediately, and the companies anticipate the trial will test up to 400 patients. Sarilumab is an infection-fighting…
Don’t Forget the Host: COVID-19 Cytokine Storm
The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.
Winter 2020’s Awards, Appointments & Announcements in Rheumatology
2019 Lupus Foundation of America Gary S. Gilkeson Career Development Awards Emily Smitherman, MD, assistant professor, pediatric rheumatology, University of Alabama at Birmingham, and Children’s of Alabama, one of four recipients of the Gary S. Gilkeson Career Development Awards, is interested in identifying predictors for differences in disease activity within the pediatric population. To accomplish…
Pediatric Cases Require Special Considerations & Aggressive Treatment Plans
ATLANTA—Managing pediatric patients with rheumatic disease involves special considerations, such as developmental concerns and physiological traits that may affect dosing of medications, according to two experts. During a session at the 2019 ACR/ARP Annual Meeting, Courtney Kremer, ARNP, a pediatric nurse practitioner at the University of Iowa Stead Family Children’s Hospital, Iowa City, and Jessica…
- « Previous Page
- 1
- …
- 213
- 214
- 215
- 216
- 217
- …
- 816
- Next Page »